These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 23244419

  • 1. C. elegans as a genetic model system to identify Parkinson's disease-associated therapeutic targets.
    Vistbakka J, VanDuyn N, Wong G, Nass R.
    CNS Neurol Disord Drug Targets; 2012 Dec; 11(8):957-64. PubMed ID: 23244419
    [Abstract] [Full Text] [Related]

  • 2. Caenorhabditis elegans as a model system for Parkinson's disease.
    Schmidt E, Seifert M, Baumeister R.
    Neurodegener Dis; 2007 Dec; 4(2-3):199-217. PubMed ID: 17596715
    [Abstract] [Full Text] [Related]

  • 3. Caenohabditis elegans in Parkinson's disease drug discovery: addressing an unmet medical need.
    Nass R, Merchant KM, Ryan T.
    Mol Interv; 2008 Dec; 8(6):284-93. PubMed ID: 19144901
    [Abstract] [Full Text] [Related]

  • 4. Caenorhabditis elegans as an experimental tool for the study of complex neurological diseases: Parkinson's disease, Alzheimer's disease and autism spectrum disorder.
    Calahorro F, Ruiz-Rubio M.
    Invert Neurosci; 2011 Dec; 11(2):73-83. PubMed ID: 22068627
    [Abstract] [Full Text] [Related]

  • 5. Copper-mediated neurotoxicity and genetic vulnerability in the background of neurodegenerative diseases in C. elegans.
    Weishaupt AK, Ruecker L, Meiners T, Schwerdtle T, Silva Avila D, Aschner M, Bornhorst J.
    Toxicol Sci; 2024 Oct 01; 201(2):254-262. PubMed ID: 39067045
    [Abstract] [Full Text] [Related]

  • 6. C. elegans as a model organism to investigate molecular pathways involved with Parkinson's disease.
    Harrington AJ, Hamamichi S, Caldwell GA, Caldwell KA.
    Dev Dyn; 2010 May 01; 239(5):1282-95. PubMed ID: 20108318
    [Abstract] [Full Text] [Related]

  • 7. Modelling Parkinson's Disease in C. elegans: Strengths and Limitations.
    Ma L, Li X, Liu C, Yan W, Ma J, Petersen RB, Peng A, Huang K.
    Curr Pharm Des; 2022 May 01; 28(37):3033-3048. PubMed ID: 36111767
    [Abstract] [Full Text] [Related]

  • 8. Insights from Caenorhabditis elegans on the role of metals in neurodegenerative diseases.
    Martinez-Finley EJ, Avila DS, Chakraborty S, Aschner M.
    Metallomics; 2011 Mar 01; 3(3):271-9. PubMed ID: 21210060
    [Abstract] [Full Text] [Related]

  • 9. Holothuria scabra extracts exhibit anti-Parkinson potential in C. elegans: A model for anti-Parkinson testing.
    Chalorak P, Jattujan P, Nobsathian S, Poomtong T, Sobhon P, Meemon K.
    Nutr Neurosci; 2018 Jul 01; 21(6):427-438. PubMed ID: 28276260
    [Abstract] [Full Text] [Related]

  • 10. C. elegans as a model system to accelerate discovery for Parkinson disease.
    Martinez BA, Caldwell KA, Caldwell GA.
    Curr Opin Genet Dev; 2017 Jun 01; 44():102-109. PubMed ID: 28242493
    [Abstract] [Full Text] [Related]

  • 11. Anti-Parkinsonian effects of β-amyrin are regulated via LGG-1 involved autophagy pathway in Caenorhabditis elegans.
    Wei CC, Chang CH, Liao VH.
    Phytomedicine; 2017 Dec 01; 36():118-125. PubMed ID: 29157804
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Study of molecular mechanism of anti-Parkinson's disease traditional Chinese medicine using model of Caenorhabditis elegans].
    Wang X, Wang X, Gao H, Wang D.
    Zhongguo Zhong Yao Za Zhi; 2010 Mar 01; 35(5):661-3. PubMed ID: 20506834
    [Abstract] [Full Text] [Related]

  • 14. Anti-Parkinsonian effects of Bacopa monnieri: insights from transgenic and pharmacological Caenorhabditis elegans models of Parkinson's disease.
    Jadiya P, Khan A, Sammi SR, Kaur S, Mir SS, Nazir A.
    Biochem Biophys Res Commun; 2011 Oct 07; 413(4):605-10. PubMed ID: 21925152
    [Abstract] [Full Text] [Related]

  • 15. Traversing a wormhole to combat Parkinson's disease.
    Caldwell GA, Caldwell KA.
    Dis Model Mech; 2008 Oct 07; 1(1):32-6. PubMed ID: 19048050
    [Abstract] [Full Text] [Related]

  • 16. Balancing Apoptosis and Autophagy for Parkinson's Disease Therapy: Targeting BCL-2.
    Liu J, Liu W, Yang H.
    ACS Chem Neurosci; 2019 Feb 20; 10(2):792-802. PubMed ID: 30400738
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Caenorhabditis elegans RAC1/ced-10 mutants as a new animal model to study very early stages of Parkinson's disease.
    Muñoz-Juan A, Benseny-Cases N, Guha S, Barba I, Caldwell KA, Caldwell GA, Agulló L, Yuste VJ, Laromaine A, Dalfó E.
    Prog Neurobiol; 2024 Mar 20; 234():102572. PubMed ID: 38253120
    [Abstract] [Full Text] [Related]

  • 19. Dysregulation of the Mitochondrial Unfolded Protein Response Induces Non-Apoptotic Dopaminergic Neurodegeneration in C. elegans Models of Parkinson's Disease.
    Martinez BA, Petersen DA, Gaeta AL, Stanley SP, Caldwell GA, Caldwell KA.
    J Neurosci; 2017 Nov 15; 37(46):11085-11100. PubMed ID: 29030433
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.